Neuroendocrine Tumors: all 682 studies
Page 2 of 7. Open to participants first (164), then studies with results posted, then the rest; newest registration first within each.
- A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the LiverNot yet recruitingNCT05647954Phase 3
- Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive TumorsRecruitingNCT05636618Phase 1/2
- EUS-FNI for Nonfunctional Pancreatic Neuroendocrine TumorsRecruitingNCT05566093Not applicable
- EUS-FNI for MEN1-related Pancreatic Neuroendocrine TumorsRecruitingNCT05554744Not applicable
- Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe StudyRecruitingNCT05554003Phase 2
- Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote MonitoringRecruitingNCT05500391Phase 2
- 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine TumorsRecruitingNCT05475210Phase 1
- TARGETed Therapy Drug MONITOring in DIGestive OncologyRecruitingNCT05443087Not applicable
- Endoscopic Resection for Small Rectal Neuroendocrine TumorsNot yet recruitingNCT05429216Not applicable
- Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer PatientsEnrolling by invitationNCT05396118Phase 2
- Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.RecruitingNCT05387603Phase 3
- Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)RecruitingNCT05359146Early Phase 1
- Financial Toxicity and Patient-Reported Outcomes in GEP-NEN During TreatmentRecruitingNCT05334290
- Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine NeoplasmsNot yet recruitingNCT05316480Phase 2
- A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)RecruitingNCT05268952Not applicable
- Patient-reported Outcomes in Neuroendocrine Neoplasms: a Prospective Quality of Life and Quality of Care Study Within NETwerkRecruitingNCT05268783Not applicable
- Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine TumorsRecruitingNCT05263050Phase 2
- Endoscopic Ultrasound Guided Radio Frequency Ablation of Pancreatic Neuroendocrine NeoplasmsRecruitingNCT05243082Not applicable
- Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)RecruitingNCT05237934
- Lutathera and ASTX727 in Neuroendocrine TumoursRecruitingNCT05178693Phase 1
- Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)RecruitingNCT05165407Phase 2
- A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDGEnrolling by invitationNCT05160480
- 18F-MFBG PET/CT in the Evaluation of Neural Crest TumorRecruitingNCT05069220Early Phase 1
- PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine TumoursRecruitingNCT05053854Phase 1
- Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine TumorsRecruitingNCT05048901Phase 1/2
- Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesRecruitingNCT05000294Phase 1/2
- Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NETRecruitingNCT04954820Phase 2
- Spanish Series of Patients Treated With the Radionuclide Lutetium177RecruitingNCT04949282
- Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN PatientsRecruitingNCT04917484Phase 2
- Virtual Reality for GI Cancer Pain to Improve Patient Reported OutcomesRecruitingNCT04907643Not applicable
- A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)RecruitingNCT04893785Phase 2
- Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent TumorsNot yet recruitingNCT04889742Phase 2
- 68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive TumorsRecruitingNCT04888481Phase 2
- 68Ga-DOTA-TATE PET/CT Imaging in NETsRecruitingNCT04847505Phase 3
- Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver MetastasesRecruitingNCT04837885Phase 2
- Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort StudyNot yet recruitingNCT04788927
- Prophylactic Cholecystectomy in Midgut NETs Patients Who Require Primary Tumor Surgery.RecruitingNCT04735198Not applicable
- 18F-DOPA II - PET Imaging OptimizationRecruitingNCT04706910Phase 3
- Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine TumorsRecruitingNCT04520932Not applicable
- Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)RecruitingNCT04464122
- Registry on NEN Patients and COVID-19RecruitingNCT04444401
- Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 YearsRecruitingNCT04373564Phase 4
- CapTemY90 for Grade 2/3 NET Liver MetastasesRecruitingNCT04339036Phase 2
- Mobile Application to Collect PRO Data in NET PatientsRecruitingNCT04324502
- Protocol ITANET - RegistryRecruitingNCT04282083
- A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.RecruitingNCT04166006Phase 2
- Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsRecruitingNCT04119024Phase 1
- Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine DepartmentRecruitingNCT04104529Not applicable
- Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine TumorsRecruitingNCT04090034
- Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)RecruitingNCT04086485Phase 1/2
- Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine TumorsRecruitingNCT04074135Phase 2
- Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System TreatmentRecruitingNCT04066322
- A Phase I/II Study of Regorafenib Plus Avelumab in Solid TumorsRecruitingNCT03475953Phase 1/2
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruitingNCT03452774
- Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic CancerRecruitingNCT03412877Phase 2
- Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ ParagangliomaRecruitingNCT03206060Phase 2
- A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsRecruitingNCT03093116Phase 1/2
- Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 PatientsRecruitingNCT03048266
- Project: Every Child for Younger Patients With CancerRecruitingNCT02402244
- RegisterNET - A Registry for Neuroendocrine Tumors in the USA and WorldwideEnrolling by invitationNCT02270567
- Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver MetastasesRecruitingNCT02185443Phase 2
- Dose-defining Study of Tirapazamine Combined With Embolization in Liver CancerRecruitingNCT02174549Phase 1/2
- Integrated Cancer Repository for Cancer ResearchRecruitingNCT02012699
- Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch StudiesEnrolling by invitationNCT00923026
- Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of TreatmentActive, not recruitingNCT06502977Phase 2Results posted
- Evaluation of [18F]Fluoroethyl Triazole Labelled [Tyr3]-Octreotate Analogues for the Imaging of Neuroendocrine Tumours.CompletedNCT06456723Phase 1/2Results posted
- Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR InhibitorsCompletedNCT05997056Phase 2Results posted
- Dual-Tracer Theranostic PETCompletedNCT05680675Not applicableResults posted
- Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid SyndromeCompletedNCT05361668Phase 2Results posted
- Role of Proton Pump Inhibitors on the Postoperative Course Following PancreaticoduodenectomyTerminatedNCT05251233Phase 2Results posted
- Nutrition in Gastroenteropancreatic Neuroendocrine TumorCompletedNCT04986085Results posted
- Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETsCompletedNCT04852679Phase 3Results posted
- Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate CancerActive, not recruitingNCT04848337Phase 2Results posted
- Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine TumorActive, not recruitingNCT04810091Phase 3Results posted
- A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsTerminatedNCT04644315Phase 2Results posted
- Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid TumorsTerminatedNCT04579757Phase 1/2Results posted
- Open-Label Surufatinib in European Patients With NETTerminatedNCT04579679Phase 2Results posted
- Telotristat With Lutathera in Neuroendocrine TumorsTerminatedNCT04543955Phase 2Results posted
- Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) PatientsCompletedNCT04524442Phase 4Results posted
- Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN StudyCompletedNCT04400474Phase 2Results posted
- Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine TumorsActive, not recruitingNCT04234568Phase 1Results posted
- Cabozantinib and Nivolumab for Carcinoid TumorsCompletedNCT04197310Phase 2Results posted
- Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine TumorsActive, not recruitingNCT04079712Phase 2Results posted
- Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.CompletedNCT03980925Phase 2Results posted
- Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATECompletedNCT03673943Phase 3Results posted
- A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic SystemTerminatedNCT03670030Phase 2Results posted
- Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver MetastasesCompletedNCT03457948Phase 2Results posted
- AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine NeoplasmCompletedNCT03453489Phase 2Results posted
- Nivolumab With Ipilimumab in Subjects With Neuroendocrine TumorsTerminatedNCT03420521Phase 2Results posted
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsActive, not recruitingNCT03375320Phase 3Results posted
- PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic MalignanciesCompletedNCT03365791Phase 2Results posted
- Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine TumorsCompletedNCT03290079Phase 2Results posted
- A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus LanreotideCompletedNCT03289741Phase 4Results posted
- Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)CompletedNCT03273712Phase 2Results posted
- To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)CompletedNCT03220217Phase 2Results posted
- Entinostat Neuroendocrine (NE) TumorTerminatedNCT03211988Phase 2Results posted
- Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine CarcinomaTerminatedNCT03190213Phase 2Results posted
- Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT ScanCompletedNCT03136328Phase 3Results posted
- Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung OriginCompletedNCT03095274Phase 2Results posted
- A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine TumorsCompletedNCT03070301Phase 2Results posted